Amplify US Cannabis ETF
ETF providing concentrated exposure to US cannabis operators and ancillary businesses.
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Amplify Seymour Cannabis ETF earns a Neutral rating in the Neutral band, with a composite score of 36 and conviction at 3/5. Regulatory exposure is the strongest pillar at 55, supported by a global-jurisdiction posture score of 70 and an enforcement subscore of 80. Fundamentals contribute 40 despite unavailable company-level financial data, while editorial registers 30 on limited coverage. Market performance is the principal constraint at 15, reflecting the weakest contribution across the framework and preventing the regulatory profile from translating into a more constructive rating.
Licensed fundamentals data provide no revenue-growth or margin record for the ETF, leaving the financial condition unknown and limiting evidence for earnings quality, operating leverage, or portfolio-level profitability. Primary regulatory filings show no latest filing date and no recorded events across either the 90-day or 180-day observation windows. That sparse cadence produces a filing-cadence subscore of 25, materially below the jurisdiction and enforcement components, although no enforcement hits support the stronger enforcement assessment. Institutional pricing feeds record zero volume, aligning with the liquidity subscore of 15 and signaling minimal observable trading participation. CIN newsroom coverage records no newsroom hits and no brief hits, leaving both editorial subscores at 30 and offering no coverage-based uplift.
The forward catalyst sits squarely within the regulatory pillar, where the favorable global posture and clean enforcement record already provide the strongest foundation. A new primary regulatory filing or a recorded policy event would improve visibility, validate cadence, and potentially lift the composite without relying on unavailable revenue or margin data. Such activity could also generate CIN newsroom coverage, strengthening the editorial pillar, but the direct rating impact remains most closely tied to regulatory documentation. Market participation remains a secondary confirmation signal because zero recorded volume keeps liquidity at the bottom of the framework. The single most important signal to watch is the appearance of a new primary regulatory filing that raises the cadence assessment.
- IR email
- info@amplifyetfs.com
- Headquarters
- 3333 Warrenville Road Suite 350 Lisle, IL 60532
- Phone
- (855) 267-3837
- CEO
- William Belden President Bradley
- CFO
- Robin Tardy National Sales
- Website
- Company website
- Beta
- 0.92
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Amplify US Cannabis ETF (CNBS): ETF Overview
Amplify US Cannabis ETF is a cannabis-sector exchange-traded fund tracked by Cannabis Investor News. Holdings, top weights, fund flows, and performance metrics are updated alongside live pricing.
ETF providing concentrated exposure to US cannabis operators and ancillary businesses.
Latest price: $28.26 (-1.52%) on NYSEARCA.
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for CNBS are maintained by Cannabis Investor News and refreshed throughout the trading day.